147 related articles for article (PubMed ID: 29656432)
1. Calcium channel blockers and the incidence of breast and prostate cancer: A meta-analysis.
Thakur AA; Wang X; Garcia-Betancourt MM; Forse RA
J Clin Pharm Ther; 2018 Aug; 43(4):519-529. PubMed ID: 29656432
[TBL] [Abstract][Full Text] [Related]
2. Association Between the Overall Risk of Prostate Cancer and Use of Calcium Channel Blockers: A Systematic Review and Meta-analysis.
Yang H; Yu Y; Hu X; Wang W; Yang X; Liu H; Ren L; Zhang X; Feng X; Liu L
Clin Ther; 2020 Sep; 42(9):1715-1727.e2. PubMed ID: 32807506
[TBL] [Abstract][Full Text] [Related]
3. The Risk for Prostate Cancer With Calcium Channel Blockers: A Systematic Review, Meta-Analysis, and Meta-Regression.
Rotshild V; Rabkin N; Matok I
Ann Pharmacother; 2023 Jan; 57(1):16-28. PubMed ID: 35645169
[TBL] [Abstract][Full Text] [Related]
4. Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies.
Chen Q; Zhang Q; Zhong F; Guo S; Jin Z; Shi W; Chen C; He J
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):711-8. PubMed ID: 24829113
[TBL] [Abstract][Full Text] [Related]
5. Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population-Based Nested Case-Control Study.
Rotshild V; Azoulay L; Feldhamer I; Perlman A; Muszkat M; Matok I
Pharmacotherapy; 2019 Jun; 39(6):690-696. PubMed ID: 30917404
[TBL] [Abstract][Full Text] [Related]
6. Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD).
Grimaldi-Bensouda L; Klungel O; Kurz X; de Groot MC; Maciel Afonso AS; de Bruin ML; Reynolds R; Rossignol M
BMJ Open; 2016 Jan; 6(1):e009147. PubMed ID: 26747033
[TBL] [Abstract][Full Text] [Related]
7. The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies.
Rotshild V; Azoulay L; Zarifeh M; Masarwa R; Hirsh-Raccah B; Perlman A; Muszkat M; Matok I
Drug Saf; 2018 Jun; 41(6):555-564. PubMed ID: 29484611
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel blockers and breast cancer incidence: An updated systematic review and meta-analysis of the evidence.
Wright CM; Moorin RE; Chowdhury EK; Stricker BH; Reid CM; Saunders CM; Hughes JD
Cancer Epidemiol; 2017 Oct; 50(Pt A):113-124. PubMed ID: 28866282
[TBL] [Abstract][Full Text] [Related]
9. Risk of Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme Inhibitors Among Older Women.
Raebel MA; Zeng C; Cheetham TC; Smith DH; Feigelson HS; Carroll NM; Goddard K; Tavel HM; Boudreau DM; Shetterly S; Xu S
Am J Epidemiol; 2017 Feb; 185(4):264-273. PubMed ID: 28186527
[TBL] [Abstract][Full Text] [Related]
10. The association between calcium channel blocker use and prostate cancer outcome.
Poch MA; Mehedint D; Green DJ; Payne-Ondracek R; Fontham ET; Bensen JT; Attwood K; Wilding GE; Guru KA; Underwood W; Mohler JL; Heemers HV
Prostate; 2013 Jun; 73(8):865-72. PubMed ID: 23280547
[TBL] [Abstract][Full Text] [Related]
11. Systematic review with meta-analysis: the association between the use of calcium channel blockers and gastrointestinal bleeding.
He Y; Chan EW; Leung WK; Anand S; Wong IC
Aliment Pharmacol Ther; 2015 Jun; 41(12):1246-55. PubMed ID: 25898902
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies.
Cao L; Zhang S; Jia CM; He W; Wu LT; Li YQ; Wang W; Li Z; Ma J
BMC Urol; 2018 Mar; 18(1):17. PubMed ID: 29514670
[TBL] [Abstract][Full Text] [Related]
13. Postdiagnostic Calcium Channel Blocker Use and Breast Cancer Mortality: A Population-based Cohort Study.
Busby J; Mills K; Zhang SD; Liberante FG; Cardwell CR
Epidemiology; 2018 May; 29(3):407-413. PubMed ID: 29608546
[TBL] [Abstract][Full Text] [Related]
14. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group.
Braun S; Boyko V; Behar S; Reicher-Reiss H; Laniado S; Kaplinsky E; Goldbourt U
J Am Coll Cardiol; 1998 Mar; 31(4):804-8. PubMed ID: 9525550
[TBL] [Abstract][Full Text] [Related]
15. Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis.
Lang Y; Gong D; Fan Y
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):559-66. PubMed ID: 25845582
[TBL] [Abstract][Full Text] [Related]
16. No Association Between Calcium Channel Blockers and Survival in Patients with Cancer: A Systematic Review and Meta-analysis.
Sun H; Zhuang RY; Li T; Zheng YT; Cai WM
Asian Pac J Cancer Prev; 2016; 17(8):3917-21. PubMed ID: 27644639
[TBL] [Abstract][Full Text] [Related]
17. Antiarrhythmic drug usage and prostate cancer: a population-based cohort study.
Kao LT; Huang CC; Lin HC; Huang CY
Asian J Androl; 2018; 20(1):37-42. PubMed ID: 28857052
[TBL] [Abstract][Full Text] [Related]
18. Protective Association Between Calcium Channel Blocker Use and Breast Cancer Recurrence in Postsurgical Women: A Population-Based Case-Control Study in Taiwan.
Shih JH; Kao LT; Chung CH; Liao GS; Fann LY; Chien WC; Li IH
J Clin Pharmacol; 2020 Jun; 60(6):785-792. PubMed ID: 32020656
[TBL] [Abstract][Full Text] [Related]
19. Association between long-term use of calcium channel blockers (CCB) and the risk of breast cancer: a retrospective longitudinal observational study protocol.
Ho C; Ha NT; Youens D; Abhayaratna WP; Bulsara MK; Hughes JD; Mishra G; Pearson SA; Preen DB; Reid CM; Ruiter R; Saunders CM; Stricker BH; van Rooij FJA; Wright C; Moorin R
BMJ Open; 2024 Mar; 14(3):e080982. PubMed ID: 38458796
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
